CN109790219A - 使用lilotomab和177Lu-lilotomab satetraxetan治疗非霍奇金淋巴瘤 - Google Patents

使用lilotomab和177Lu-lilotomab satetraxetan治疗非霍奇金淋巴瘤 Download PDF

Info

Publication number
CN109790219A
CN109790219A CN201780055437.7A CN201780055437A CN109790219A CN 109790219 A CN109790219 A CN 109790219A CN 201780055437 A CN201780055437 A CN 201780055437A CN 109790219 A CN109790219 A CN 109790219A
Authority
CN
China
Prior art keywords
lilotomab
satetraxetan
administration
lilotomab satetraxetan
hodgkin lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780055437.7A
Other languages
English (en)
Chinese (zh)
Inventor
乔斯坦·达勒
西蒙·特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thor Medical ASA
Original Assignee
Nordic Nanovector AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector AS filed Critical Nordic Nanovector AS
Publication of CN109790219A publication Critical patent/CN109790219A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201780055437.7A 2016-09-16 2017-09-15 使用lilotomab和177Lu-lilotomab satetraxetan治疗非霍奇金淋巴瘤 Pending CN109790219A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16189191.6 2016-09-16
EP16189191 2016-09-16
EP17164164.0 2017-03-31
EP17164164 2017-03-31
EP17170641 2017-05-11
EP17170641.9 2017-05-11
EP17175768.5 2017-06-13
EP17175768 2017-06-13
PCT/EP2017/073336 WO2018050851A1 (en) 2016-09-16 2017-09-15 Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan

Publications (1)

Publication Number Publication Date
CN109790219A true CN109790219A (zh) 2019-05-21

Family

ID=59895313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780055437.7A Pending CN109790219A (zh) 2016-09-16 2017-09-15 使用lilotomab和177Lu-lilotomab satetraxetan治疗非霍奇金淋巴瘤

Country Status (14)

Country Link
US (2) US20190192703A1 (https=)
EP (1) EP3512881A1 (https=)
JP (1) JP2019529433A (https=)
KR (1) KR20190054113A (https=)
CN (1) CN109790219A (https=)
AU (1) AU2017327772A1 (https=)
BR (1) BR112019004838A2 (https=)
CA (1) CA3035268A1 (https=)
IL (1) IL265387A (https=)
MX (1) MX2019003029A (https=)
PH (1) PH12019550033A1 (https=)
RU (1) RU2019110955A (https=)
SG (2) SG11201901672RA (https=)
WO (1) WO2018050851A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102688509B1 (ko) * 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
KR20240083769A (ko) 2022-12-05 2024-06-12 김원석 휴대할 수 있는 해수 정화 유닛용 물통

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259270A (zh) * 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
US20140348745A1 (en) * 2011-12-13 2014-11-27 Nordic Nanovector As Chimeric therapeutic anti - cd37 antibodie hh1
CN104338154A (zh) * 2010-01-29 2015-02-11 诺帝克纳诺维科特公司 放射免疫偶联物和其用途
WO2016138034A1 (en) * 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259270A (zh) * 1999-08-11 2008-09-10 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
CN104338154A (zh) * 2010-01-29 2015-02-11 诺帝克纳诺维科特公司 放射免疫偶联物和其用途
US20140348745A1 (en) * 2011-12-13 2014-11-27 Nordic Nanovector As Chimeric therapeutic anti - cd37 antibodie hh1
WO2016138034A1 (en) * 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHAN BLAKKISRUD等: "Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate", 《THE JOURNAL OF NUCLEAR MEDICINE》 *
JOHAN BLAKKISRUD等: "Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan", 《THE JOURNAL OF NUCLEAR MEDICINE》 *
张军一等: "治疗非霍奇金淋巴瘤的新药介绍", 《中国处方药》 *

Also Published As

Publication number Publication date
PH12019550033A1 (en) 2019-07-29
CA3035268A1 (en) 2018-03-22
SG11201901672RA (en) 2019-03-28
AU2017327772A1 (en) 2019-03-21
IL265387A (en) 2019-05-30
RU2019110955A3 (https=) 2020-11-26
BR112019004838A2 (pt) 2019-06-04
EP3512881A1 (en) 2019-07-24
KR20190054113A (ko) 2019-05-21
US20190192703A1 (en) 2019-06-27
SG10202102588QA (en) 2021-04-29
WO2018050851A1 (en) 2018-03-22
US20220160907A1 (en) 2022-05-26
MX2019003029A (es) 2019-09-13
RU2019110955A (ru) 2020-10-20
JP2019529433A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
Seidl Radioimmunotherapy with α-particle-emitting radionuclides
Alam et al. A review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging theranostic agents in prostate cancer
Behr et al. High‐dose myeloablative radioimmunotherapy of mantle cell non‐hodgkin lymphoma with the iodine‐131–labeled chimeric anti‐CD20 antibody C2B8 and autologous stem cell support.[THIS ARTICLE HAS BEEN RETRACTED] Results of a pilot study
Rao et al. Radioimmunotherapy for non-Hodgkin’s lymphoma
Schoffelen et al. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer
Bodet-Milin et al. Radioimmunotherapy for treatment of acute leukemia
RU2770073C2 (ru) Радиотерапевтические частицы и суспензии
Cicone et al. Radioimmunotherapy of non-Hodgkin B-cell lymphoma: an update
US20220160907A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
Taunk et al. Radiopharmaceuticals for cancer diagnosis and therapy: new targets, new therapies—alpha-emitters, novel targets
Lindén et al. A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and90Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma
Cilley et al. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas
Koenecke et al. Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia
NO332931B1 (no) Anvendelse av kompleks av thorium-227 og komplekseringsmiddel i fremstilling av et medikament, farmasoytisk sammensetning omfattende mykvevsmalrettingskompleks, mykvevsmalrettingskompleks, fremgangsmate for a danne et kompleks samt sett for bruk i anvendelsen.
Vallabhajosula Radiopharmaceuticals for therapy
Bailly et al. Radioimmunotherapy of lymphomas
Yadav et al. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma
Buchmann et al. Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?
Ng Radioimmunotherapy: a brief overview
US20110300067A1 (en) Methods for increasing efficacy of radioimmunotherapy of melanoma
Pandit-Taskar et al. New strategies in radioimmunotherapy for lymphoma
Rathmann Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry
Sharda et al. Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis
Sowa Dumond et al. Concepts and issues for therapeutic radiopharmaceuticals
Palm et al. Patient-specific alpha-particle dosimetry

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190521